Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
BioPharm Insight
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
 
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Apr 30, 2010 |
Aurora Diagnostics Inc. |
N/A |
N/A |
N/A |
$150M |
N/A |
N/A |
Lead Underwriter |
Morgan Stanley, Barclays Capital and UBS Investment Bank |
Description |
Aurora Diagnostics, LLC is a specialized laboratory company consisting of anatomic pathology and other diagnostic laboratory businesses. |
| Apr 7, 2010 |
Alimera Sciences Inc. |
N/A |
$15-17/Per Share |
N/A |
$87M |
N/A |
N/A |
Lead Underwriter |
Credit Suisse Securities LLC |
Description |
Alimera Sciences, Inc., is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceutical. |
| Dec 30, 2009 |
Med BioGene |
N/A |
N/A |
N/A |
$24.25M |
N/A |
N/A |
Lead Underwriter |
Rodman & Renshaw, LLC |
Description |
MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Dec 29, 2009 |
Codexis Pharmaceuticals |
N/A |
N/A |
N/A |
$100M |
N/A |
N/A |
Lead Underwriter |
Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. will be acting as joint book-running managers, with RBC Capital Markets Corporation and Pacific Crest Securities LLC acting as co-managers for the offering. |
Description |
Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and has the potential to make new industrial processes possible at commercial scale. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Dec 28, 2009 |
Tengion Inc. |
N/A |
N/A |
N/A |
$40.25M |
N/A |
N/A |
Lead Underwriter |
Piper Jaffray & Co. is acting as the sole manager. |
Description |
Tengion is a clinical-stage company focused on discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Dec 17, 2009 |
AVEO Pharmaceuticals, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
The joint book-running managers of the proposed offering will be J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated. Leerink Swann LLC will be the lead co-manager and Canaccord Adams Inc. will be a co-manager. |
Description |
AVEO is a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Dec 10, 2009 |
China Nuokang Bio-Pharmaceutical Inc. |
N/A |
N/A |
N/A |
$45M |
N/A |
N/A |
Lead Underwriter |
Jefferies & Company acted as the sole bookrunner and Oppenheimer & Co. acted as co-manager for the offering. |
Description |
Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Nov 9, 2009 |
Trius Therapeutics |
N/A |
N/A |
N/A |
$86.25M |
N/A |
N/A |
Lead Underwriter |
Credit Suisse |
Description |
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Oct 30, 2009 |
Aldagen Inc. |
ALDH |
N/A |
N/A |
$80.5M |
N/A |
N/A |
Lead Underwriter |
Cowen and Co, Wachovia Securities, and Pacific Growth Equities |
Description |
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Sep 16, 2008 |
Mead Johnson Nutrition Company |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Citigroup Global Markets Inc. and Morgan Stanley & Co. Incorporated |
Description |
Mead Johnson Nutrition helps moms make sure those babies grow up healthy. The company, a subsidiary of pharmaceutical manufacturer Bristol-Myers Squibb (BMS), specializes in making nutritional products for infants and children. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jul 25, 2008 |
AutoGenomics, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
J.P. Morgan Securities Inc., Deutsche Bank Securities Inc., Pacific Growth Equities, LLC and Robert W. Baird & Co. |
Description |
AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jul 2, 2008 |
Alimera Sciences Inc. |
N/A |
N/A |
N/A |
$75M |
N/A |
N/A |
Lead Underwriter |
Credit Suisse, Citi, Cowen and Co, and Leerink Swann |
Description |
Alimera Sciences, Inc., incorporated on June 4, 2003, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jun 18, 2008 |
Genomma |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
IXE Casa de Bolsa, S.A. de C.V., and Casa de Bolsa Santander, S.A. de C.V. |
Description |
Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico. Genomma trades on the Mexican Stock Exchange under the ticker symbol LAB. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jun 11, 2008 |
ZARS, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Cowen and Company and CIBC World Markets are joint book running managers for the offering. Leerink Swann & Company and Susquehanna Financial Group, LLLP are comanagers. |
Description |
ZARS, Inc. is a specialty pharmaceutical company focused on the development and commercialization of topically applied drugs using its proprietary drug delivery technologies, with an initial focus on pain management. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Apr 18, 2008 |
Epocrates, Inc. |
N/A |
N/A |
N/A |
$75M |
N/A |
N/A |
Lead Underwriter |
Citi, Piper Jaffray, William Blair & Co, and Needham & Co. |
Description |
Epocrates, Inc. develops clinical information and decision support tools that enable healthcare professionals to find answers more quickly and confidently at the point of care. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Apr 16, 2008 |
Fluidigm Corporation |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Morgan Stanley & Co. Incorporated is acting as book-running manager, with UBS Investment Bank and Leerink Swann & Company acting as co-managers. |
Description |
Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit systems for life science research. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Mar 10, 2008 |
Bostwick Laboratories |
N/A |
N/A |
N/A |
$100M |
N/A |
N/A |
Lead Underwriter |
Banc of America Securities LLC, Wachovia Securities, William Blair & Co, and Cowen & Co. |
Description |
Bostwick Laboratories is a full-service laboratory specializing in uropathology, featuring a staff of board-certified, internationally renowned pathologists dedicated to the diagnosis, treatment and subsequent management of prostate cancer, kidney disease, cancer of the bladder and other urologic conditions. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jan 28, 2008 |
Phenomix Corporation |
N/A |
N/A |
N/A |
$86.25M |
N/A |
N/A |
Lead Underwriter |
Morgan Stanley, Credit Suisse, Oppenheimer & Co. and Pacific Growth Equities. |
Description |
Phenomix is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jan 10, 2008 |
Omeros Corporation |
N/A |
N/A |
N/A |
$115M |
N/A |
N/A |
Lead Underwriter |
Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co- lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. |
Description |
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jan 9, 2008 |
Bayhill Therapeutics, Inc. |
N/A |
N/A |
N/A |
$86.25M |
N/A |
N/A |
Lead Underwriter |
Pacific Growth Equities LLC, Lazard Capital Markets, Merriman Curhan Ford & Co and Punk, Ziegel & Co. |
Description |
Bayhill Therapeutics, Inc. is a clinical-stage biopharmaceutical company using its proprietary therapeutic platform to develop a pipeline of novel products to treat autoimmune diseases in a fundamentally new manner. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 24, 2007 |
Precision Therapeutics, Inc. |
N/A |
N/A |
N/A |
$80.5M |
N/A |
N/A |
Lead Underwriter |
JP Morgan Securities Inc, Piper Jaffray & Co and JMP Securities LLC. |
Description |
The company develops and commercializes tests intended to assist physicians in individualizing cancer therapy. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 22, 2007 |
Adnexus Therapeutics Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Lehman Brothers, UBS Investment Bank, Cowen and Co. and Lazard Capital Markets. |
Description |
Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of a new class of drugs, Adnectins. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 21, 2007 |
BioForm Medical Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
JPMorgan, Piper Jaffray, CIBC World Markets and Jefferies & Company. |
Description |
BioForm Medical, Inc. is a privately-held medical aesthetics company headquartered in San Mateo, California. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 14, 2007 |
Biolex, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Lehman Brothers Inc. and Deutsche Bank Securities Inc. are acting as joint book-running managers and Leerink Swann & Co., Inc. is acting as co-manager for the offering. |
Description |
Biolex is a clinical-stage biopharmaceutical company that uses its patented LEX System(SM) to develop hard-to-make therapeutic proteins and to optimize monoclonal antibodies. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 10, 2007 |
Reliant Pharmaceuticals, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Goldman, Sachs & Co. and Merrill Lynch & Co. will act as the joint lead managers and joint book-runners for the proposed offering. |
Description |
Reliant Pharmaceuticals is a pharmaceutical company that specializes in the development, commercialization and marketing of prescription therapeutic products. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 10, 2007 |
Novabay Pharmaceuticals |
NBY |
$4-$6 |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Dundee Securities Inc. and Blackmont Capital Corp., among others, are underwriting the IPO. |
Description |
NovaBay Pharmaceuticals is a clinical-stage pharmaceutical company developing a new class of compounds: The Aganocide™ compounds. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 7, 2007 |
BG Medicine |
BGMDX |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Cowen International Limited and Fortis will be acting as joint global coordinators and joint book-runners for the offering. Leerink Swann & Company will act as co-manager. |
Description |
BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 3, 2007 |
Sucampo Pharmaceuticals, Inc. |
SCMP |
$11.50 |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Cowen and Company, LLC is acting as the book-running manager for the offering and CIBC World Markets Corp. and Leerink Swann & Company are acting as co-managers. |
Description |
Sucampo is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jul 30, 2007 |
Talecris Biotherapeutics Holdings Corp. |
TLCR |
N/A |
N/A |
$1B |
N/A |
N/A |
Lead Underwriter |
Morgan Stanley, Goldman Sachs & Co. and JPMorgan. |
Description |
Talecris Biotherapeutics discovers, develops, and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jul 13, 2007 |
Bioheart, Inc. |
N/A |
N/A |
N/A |
$45M |
N/A |
N/A |
Lead Underwriter |
BMO Capital Markets, Janney Montgomery Scott LLC and Merriman Curhan Ford & Co. were listed as underwriters for the offering. |
Description |
Bioheart is using cells from a patient's own body to develop therapies for the treatment of heart diseases. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jun 18, 2007 |
MAP Pharmaceuticals, Inc. |
N/A |
$14-$16 |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Merrill Lynch & Co. and Morgan Stanley & Co. Incorporated are joint book-running managers for the offering. Deutsche Bank Securities Inc. is co-lead manager. |
Description |
MAP Pharmaceuticals is a product based biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases. MAP Pharmaceuticals' principal product development strategy is to create innovative therapies with large market potential to improve safety, efficacy, and patient compliance. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jun 11, 2007 |
Zars, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Cowen and Company and CIBC World Markets are joint book running managers for the offering. Leerink Swann & Company and Susquehanna Financial Group, LLLP are comanagers. |
Description |
ZARS, Inc. is a specialty pharmaceutical company focused on the development and commercialization of topically applied drugs using its proprietary drug delivery technologies, with an initial focus on pain management. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jun 5, 2007 |
Quark Pharmaceuticals |
QURK |
$12-$14 |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
JPMorgan Chase and Bank of America. |
Description |
Quark is an evolving pharmaceutical company using rational drug design to develop new therapeutics for unmet medical needs. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| May 11, 2007 |
Targanta Therapeutics |
N/A |
N/A |
N/A |
$86.25M |
N/A |
N/A |
Lead Underwriter |
Credit Suisse, Cowen and Co., Lazard Capital Markets, and Leerink Swann & Co. |
Description |
The Cambridge, Massachusetts-based company, develops antibiotics for serious infections treated or acquired in hospitals. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| May 7, 2007 |
ImaRx Therapeutics |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter |
Maxim Group, LLC |
Description |
ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| May 2, 2007 |
Cumberland Pharmaceuticals Inc. |
CPIX |
N/A |
N/A |
$115M |
N/A |
N/A |
Lead Underwriter |
UBS Investment Bank, Jefferies & Company, Wachovia Securities and Morgan Joseph |
Description |
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. |
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Mar 21, 2007 |
Aegerion Pharmaceuticals, Inc. |
AEGR |
N/A |
N/A |
$86.25M |
N/A |
N/A |
Lead Underwriter
|
Lehman Brothers Inc., CIBC World Markets Corp., Thomas Weisel Partners LLC, C.E. Unterberg, Towbin LLC are listed as the underwriters.
|
Description
|
Incorporated in February 2005 and headquartered in Bridgewater, New Jersey, Aegerion Pharmaceuticals is a specialty pharmaceutical company focusing on the development and commercialization of promising therapeutics to treat cardiovascular / metabolic disease.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Mar 9, 2007 |
Jazz Pharmaceuticals, Inc. |
JAZZ |
N/A |
N/A |
$172.5M |
N/A |
N/A |
Lead Underwriter
|
The offering is being made through Morgan Stanley, Lehman Brothers, Credit Suisse, and Natexis Bleichroeder.
|
Description
|
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Mar 1, 2007 |
Helicos BioSciences Corporation |
HLCS |
N/A |
N/A |
$100M |
N/A |
N/A |
Lead Underwriter
|
UBS Investment Bank will be acting as the sole book-running manager for the offering. J.P. Morgan Securities Inc. is acting as a joint lead manager, with Leerink Swann & Company and Pacific Growth Equities, LLC acting as co-managers.
|
Description
|
Helicos BioSciences Corporation is a life sciences company developing innovative genetic analysis technologies for the research, drug discovery and clinical diagnostics markets.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Mar 1, 2007 |
Sirtris Pharmaceuticals
|
SIRT |
N/A |
N/A |
$60M |
N/A |
N/A |
Lead Underwriter
|
J.P. Morgan Securities Inc. will serve as the sole book-running manager for the offering. CIBC World Markets Corp., Piper Jaffray & Co., JMP Securities LLC, and Rodman & Renshaw, LLC are acting as co-managers for the offering.
|
Description
|
Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Feb 28, 2007 |
EndoCeutics
|
ENCX |
N/A |
N/A |
$75M |
N/A |
N/A |
Lead Underwriter
|
First Albany Capital, Oppenheimer & Co. and Stifel Nicolaus will underwrite the IPO.
|
Description
|
Canada's EndoCeutics Inc., a pharmaceutical firm developing hormone therapies for breast cancer and other endocrine-related disorders.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Feb 27, 2007 |
Tongjitang Chinese Medicines Company |
N/A |
$15-$17 |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Merrill Lynch & Co. and UBS Investment Bank will act as joint global coordinators and joint book runners for the offering.
|
Description
|
Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, and Tongjitang Planting, is a vertically integrated and profitable specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Feb 14, 2007 |
Bioheart, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
BMO Capital Markets Corp. will act as sole book-running manager of the proposed offering. Janney Montgomery Scott, LLC and Merriman Curhan Ford & Co. will act as co-lead manager and co-manager of the proposed offering, respectively.
|
Description
|
Bioheart, Inc. is a biotechnology company focused on the discovery, development and commercialization of therapies using cells derived from a patient's body, and related devices, for the treatment of heart damage.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Feb 7, 2007 |
Biodel Inc. |
N/A |
N/A |
N/A |
$86.25M |
N/A |
N/A |
Lead Underwriter
|
Banc of America Securities LLC and CIBC World Markets are leading the deal's underwriting.
|
Description
|
Biodel Inc. is a specialty pharmaceutical company that develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Feb 7, 2007 |
NeurogesX, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Morgan Stanley & Co. Incorporated will act as the sole book runner and lead manager for the offering. In addition, Pacific Growth Equities, LLC, Lazard Capital Markets LLC and Susquehanna Financial Group, LLLP will act as co-managers of the offering.
|
Description
|
NeurogesX is a biopharmaceutical company based in the San Francisco Bay Area. Our focus is on the development of effective treatments that relieve chronic pain and improve quality of life.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Jan 19, 2007 |
3SBio |
N/A |
N/A |
N/A |
$7.7M |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Dec 19, 2006 |
Orexigen Therapeutics, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Merrill Lynch & Company is acting as sole book-running manager and J.P. Morgan Securities Inc. is co-lead manager, with JMP Securities LLC and Leerink Swann & Company acting as co-managers for the offering.
|
Description
|
Orexigen(TM) Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders, with an initial focus on obesity.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Dec 13, 2006 |
OncoGenex Technologies Inc. |
N/A |
N/A |
N/A |
$48M |
N/A |
N/A |
Lead Underwriter
|
RBC Capital Markets will be the sole lead manager for the Offering, and the co-managers will be Needham & Company, LLC, Lazard Capital Markets LLC, Canaccord Adams Inc. and Susquehanna Financial Group, LLLP.
|
Description
|
OncoGenex is committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Nov 22, 2006 |
Synta Pharmaceuticals |
N/A |
N/A |
N/A |
$115M |
N/A |
N/A |
Lead Underwriter
|
Bear, Stearns & Co. Inc. and Lehman Brothers Inc. are acting as joint book-running managers and Lazard Capital Markets LLC and Montgomery & Co., LLC are acting as co-managers for the offering.
|
Description
|
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Nov 14, 2006 |
Accuray Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
J.P. Morgan Securities Inc. and UBS Investment Bank will be acting as joint bookrunning managers, with Piper Jaffray & Co. as lead manager and Jefferies & Company, Inc. as co-manager for the offering.
|
Description
|
Accuray designs, develops and sells the CyberKnife® System, an image- guided robotic radiosurgery system used for the treatment of solid tumors anywhere in the body.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Nov 10, 2006 |
Optimer Pharmaceuticals, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Piper Jaffray & Co. and Jefferies & Company, Inc. are acting as joint book-running managers. JMP Securities LLC and Rodman & Renshaw, LLC are acting as co-managers for the offering.
|
Description
|
Optimer Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Sep 21, 2006 |
St. Francis Medical Technologies |
N/A |
N/A |
N/A |
$86.25M |
N/A |
N/A |
Lead Underwriter
|
Citigroup Global Markets Inc. and J.P. Morgan Securities Inc. will be acting as joint bookrunning managers and Piper Jaffray & Co. and Thomas Weisel Partners LLC will be acting as co-managers.
|
Description
|
St. Francis Medical is a medical device company focused on the design, development and marketing of motion-preserving technologies and procedures for orthopedic and neurological spine surgery.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Sep 13, 2006 |
Obagi Medical Products, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
JPMorgan, CIBC World Markets, Thomas Weisel Partners LLC and Robert W. Baird & Co.
|
Description
|
Obagi Medical Products is located in Long Beach, California.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Sep 7, 2006 |
Rosetta Genomics Ltd. |
ROSG |
$11-$13 |
N/A |
$39M |
N/A |
N/A |
Lead Underwriter
|
C.E. Unterberg Towbin LLC is the lead manager and sole bookrunner, and Oppenheimer & Co. Inc. and Maxim Group LLC are co-managers.
|
Description
|
Rosetta Genomics is focused on developing diagnostic and therapeutic products for cancers and infectious diseases.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 16, 2006 |
Acologix, Inc. |
N/A |
N/A |
N/A |
$115M |
N/A |
N/A |
Lead Underwriter
|
N/A
|
Description
|
Acologix is a California-based biopharma firm developing drugs to treat renal diseases, including diseases related to hard tissues, such as bone, teeth and cartilage, as well as the kidney and associated organs.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 16, 2006 |
Hansen Medical |
HNSN |
N/A |
N/A |
$86M |
N/A |
N/A |
Lead Underwriter
|
The underwriters of the offering will be Morgan Stanley & Co. Incorporated and JP Morgan Securities Inc. as joint bookrunners and co-lead managers, and Thomas Weisel Partners LLC and Leerink Swann & Co., Inc. as co-managers.
|
Description
|
Hansen Medical Inc. is a medical robotics company.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 15, 2006 |
Emergent BioSolutions |
EBSI |
N/A |
N/A |
$86M |
N/A |
N/A |
Lead Underwriter
|
J.P. Morgan Securities Inc. will serve as sole book-running manager for the offering. Cowen and Company, LLC will be the joint lead manager, and HSBC Securities (USA) Inc. will be the co-manager for the offering.
|
Description
|
Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 14, 2006 |
ActivBiotics |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
HSBC Securities (USA) Inc. will be acting as the book-running manager and Needham & Company, LLC, BMO Capital Markets Corp. and Susquehanna Financial Group, LLLP will be acting as co-managers in this offering.
|
Description
|
ActivBiotics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of inflammatory diseases and bacterial infections.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 11, 2006 |
Virtual Radiologic |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Goldman, Sachs & Co. will act as the sole book-runner and co-lead manager, Merrill Lynch & Co. will act as co-lead manager and William Blair & Company will act as the co-manager for the proposed offering.
|
Description
|
Virtual Radiologic Corporation is a provider of remote diagnostic image interpretation, or teleradiology, services.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 11, 2006 |
Thermage, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Merrill Lynch, Pierce, Fenner & Smith Incorporated will act as the sole bookrunning manager for the offering. In addition, Thomas Weisel Partners LLC, Wachovia Capital Markets, LLC, C.E. Unterberg, Towbin, LLC and Maxim Group LLC will act as co-managers of the offering.
|
Description
|
Thermage, Inc. is a leading medical device company that manufactures and markets non-invasive treatments to tighten and contour skin
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| Aug 8, 2006 |
Xtent Inc. |
XTNT |
N/A |
N/A |
$103.5M |
N/A |
N/A |
Lead Underwriter
|
Piper Jaffray & Co. will be acting as the book-running manager and Cowen and Company LLC, Lazard Capital Markets LLC, and RBC Capital Markets are acting as co-managers.
|
Description
|
XTENT is a medical device company focused on the development and commercialization of innovative customizable drug eluting stent systems for the treatment of coronary and peripheral artery disease.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| July 31, 2006 |
Affymax, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
The underwriters of the offering will be Morgan Stanley & Co. Incorporated as sole book runner and co-lead manager, Cowen and Company, LLC and Thomas Weisel Partners LLC as co-lead managers, and RBC Capital Markets as co- manager.
|
Description
|
Affymax, Inc. is a clinical-stage biopharmaceutical company creating novel peptide-based drugs to improve the treatment of serious and often life- threatening conditions.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| July 24, 2006 |
Asthmatx, Inc. |
AZMA |
N/A |
N/A |
$75M |
N/A |
N/A |
Lead Underwriter
|
Piper Jaffray and Bear, Stearns & Co.
|
Description
|
Asthmatx, Inc. is focused on helping patients with asthma breathe easier.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| July 19, 2006 |
Innophos Holdings, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Credit Suisse Securities (USA), LLC, Bear, Stearns & Co. Inc. and UBS Investment Bank will be acting as joint book-running managers.
|
Description
|
Innophos, Inc. (http://www.innophos.com ) is one of the leading North American manufacturers of specialty phosphates, serving a diverse range of customers across multiple applications, geographies and channels.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| July 17, 2006 |
Cadence Pharmaceuticals, Inc. |
N/A |
N/A |
N/A |
$86.3M |
N/A |
N/A |
Lead Underwriter
|
Merrill Lynch & Co. is acting as sole book-running manager and Deutsche Bank Securities Inc. is acting as co-lead manager for the offering. In addition, Pacific Growth Equities, LLC and JMP Securities LLC will be acting as co-managers for the offering.
|
Description
|
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| July 17, 2006 |
Metabolix, Inc. |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Lead Underwriter
|
Piper Jaffray & Co. will be the sole book-running manager for the offering. Jefferies & Company, Inc., Thomas Weisel Partners LLC and Ardour Capital Investments, LLC will be co-managers for the offering.
|
Description
|
Metabolix is a biotechnology company that develops and plans to commercialize environmentally sustainable, economically attractive alternatives to petrochemical-based plastics, fuels and chemicals.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| July 5, 2006 |
Applied Precision, Inc. |
APLI |
N/A |
N/A |
$57.5M |
N/A |
N/A |
Lead Underwriter
|
CIBC World Markets, Cowen and Company and Canaccord Adams
|
Description
|
Applied Precision Inc.provides tools for the semiconductor and life sciences industries.
|
Filing Date |
Name |
Ticker |
Price Range |
Issue Size |
Offering Amt |
Post Offering Shares |
Est. Market Value |
| July 3, 2006 |
Oculus Innovative Sciences |
OCLS |
N/A |
N/A |
$80.5M |
N/A |
N/A |
Lead Underwriter
|
A.G. Edwards, Jefferies & Company, First Albany Capital and C.E. Unterberg Towbin
|
Description
|
Oculus Innovative Sciences Inc. makes products to help prevent and eliminate infection in chronic and acute wounds.
|
|
|
 |
|
|
|
|
|